# A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

> **NCT04623333** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Recurrent or Metastatic Cervical Cancer

## Interventions

- **DRUG:** TQB2450

## Key facts

- **NCT ID:** NCT04623333
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623333, "A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04623333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*